Analysis of the Type 2 Diabetes Therapeutics Market

9,591 views
9,188 views

Published on

The global pre-diabetes population is three times the size of the current diabetes patient population. A tremendous increase in the pandemic’s prevalence is in store, and the industry is in dire need of better tools to prevent disease progression. Identifying the precursors to fully developed diabetes through prophylactic therapy is vital, as an unexplored market segment driven by an ever-growing customer base. Meeting patients’ needs through the inclusive therapeutics approach allows practitioners to prevent and manage disease progression. This is crucial in the shift to prevention over treatment in the healthcare market and aligns with the new paradigm of physician quality over quantity.

According to Frost & Sullivan’s Competitive Intelligence research, Analysis of the Global Type 2 Diabetes Therapeutics Market, 15 new drugs for type 2 diabetes are in late-stage development (Phase 3 and preregistration). The analysis outlines opportunities in the market and the industry’s future through an international evaluation of current drugs and those in the pipeline.

For more information on Frost & Sullivan’s Life Sciences Competitive Intelligence research, please email Jennifer Carson, Corporate Communications, at jennifer.carson@frost.com, with your full name, company name, job title, telephone number, company email address, company website, city, state and country.

Published in: Health & Medicine
1 Comment
8 Likes
Statistics
Notes
  • my business wanted CG 20 37 earlier today and was told about an online service that has lots of fillable forms . If others want CG 20 37 too , here's a http://pdf.ac/1jBz2g
       Reply 
    Are you sure you want to  Yes  No
    Your message goes here
No Downloads
Views
Total views
9,591
On SlideShare
0
From Embeds
0
Number of Embeds
26
Actions
Shares
0
Downloads
389
Comments
1
Likes
8
Embeds 0
No embeds

No notes for slide

Analysis of the Type 2 Diabetes Therapeutics Market

  1. 1. Analysis of the Type 2 Diabetes Therapeutics Market Global Market Opportunities for Differentiated Therapeutics NC67-52 July 2013
  2. 2. 2NC67-52 This research service examines the global market for type 2 diabetes therapeutics. Topics covered include the following: • Market definitions including segmentation and clinical diagnostic criteria • Important trends, unmet needs, opportunities and risks in the management of type 2 diabetes Spotlight on companies and pipeline products to watch • Comprehensive product and pipeline synopses and analyses • Comparative product profile and clinical efficacy analyses • Launch timelines and patent expirations • Cardiovascular outcomes trials timeline • Segment-level forecasts and discussions of insulin and non-insulin therapeutics • Regional forecasts and discussions including evaluation of the United States, major European markets, and select Asia-Pacific markets Contents Source: Frost & Sullivan
  3. 3. 3NC67-52 • The information contained in this research service was derived from a variety of relevant primary and secondary information sources. • Primary interviews were conducted with industry participants in positions such as chairman and CEO, director of investor relations, director of business development, chief business officer, media relations, and international key opinion leaders (KOL). • Secondary data sources include disease and public health organization websites [International Diabetes federation (IDF), World Health Organization (WHO), American Diabetes Association (ADA)]; company publications (annual reports, U.S. Securities and Exchange Commission (SEC) filings, investor presentations, earnings transcripts, and press releases); government public sources; pharmaceutical industry databases; and published articles in scientific and medical journals. • For the United States, revenue forecasting is performed using a robust, data-driven, bottom-up, patient-based approach. Marketed drugs and potential new entrants in Phase 3 of development and beyond are individually forecast, and aggregate figures are provided. For other regions, forecasting is performed using a top-down model. Methodology Source: Frost & Sullivan
  4. 4. 4NC67-52 Scope and Segmentation Source: Frost & Sullivan Geographic coverage Global Study period 2009–2017 Base year 2012 Forecast period 2013—2017 Monetary unit US Dollars • This research service evaluates the global market for type 2 diabetes therapeutics. It does not evaluate other diabetes care markets such as glucose meters and supplies, insulin syringes, insulin pumps, or glucose tablets and other nutritionals. • Included are insulin and insulin analogues, oral anti-diabetic drugs (OAD) and injectable anti-diabetic drugs apart form insulin. • In-depth analysis is provided for the major markets of the United States and Europe. The emerging markets of China, South Korea, Malaysia, Indonesia, Vietnam, and India are also evaluated with an emphasis on the regional environment. • Units are patients. Treated patient numbers, when estimated, are derived from annual sales revenue and annual cost of therapy. • The price is the annual cost of therapy. Average annual cost of therapy is based on the average wholesale price (AWP) per drug, as reported in Thomson Reuters Red Book. Hospital or clinic- associated expenses are not included in the cost of therapy. • Indication-specific annual revenue as reported is used when available; otherwise, estimates are used.
  5. 5. 5NC67-52 Key Questions This Study Will Answer Source: Frost & Sullivan Is the market growing, how long will it continue to grow, and at what rate? Which segments and geographic regions are experiencing the fastest growth? How will the competitive landscape be affected by new product launches and patent expiries? How do the product profiles of new products compare to existing products? What are the remaining unmet needs of diabetes patients? How can participants and emerging competitors meet these needs? What are the major trends affecting the growth of this market? What are the biggest risks for participants or potential participants? What are the biggest opportunities and risks in emerging markets? What is the relative impact of social, economic, pricing constraints, and regulatory factors on emerging market penetration? How competitive is this market? Is this market trending toward increasing or decreasing competitiveness?
  6. 6. 6NC67-52 Insulins Total Type 2 Diabetes Therapeutics Market Total Type 2 Diabetes Therapeutics Market: Market Segmentation, Global, 2012 Non-Insulin Therapeutics Rapid insulin Add-on to SOC Premix/ Intermediate insulin Market Segmentation Source: Frost & Sullivan Standard of Care (SOC) Basal insulin Biguinides Sulfonylureas Meglitinides Glitazones Incretins SGLT2s* Human Insulin Modern Insulins *Sodium-glucose co-transporter 2 Regular insulin Premix/ Intermediate insulin
  7. 7. 7NC67-52 New Market Opportunities Source: Frost & Sullivan Unmet Needs • The most important unmet need of diabetes patients remains clinically meaningful cardiovascular benefit. • Although improvements in surrogate markers such as lipids and inflammatory biomarkers are a step in the right direction, clear demonstration of reduced risk of a cardiovascular event is critical for evidence-based medicine. • Although many newer therapies are able to more effectively manage blood glucose levels, impact on disease progression is still lacking, and most patients must still progress through an increasingly complicated therapeutic regimen, usually culminating at insulin therapy. • The population with prediabetes is estimated to be approximately three times the size of the diabetes population. Prophylactic therapy based on identified precursors to full blown diabetes is a key unmet need. Current Participant Strategies • Novo Nordisk: Meets the diverse needs of insulin patients by providing a complete insulin portfolio. Also invests in other biopharma antidiabetics such as Victoza. Novo Nordisk focuses on the highly lucrative biopharma sector where they have considerable capability and barriers to entry are higher. • Merck: Achieved market leadership among non-insulin antidiabetics with a single first-in- class blockbuster, Januvia. Januvia was the first add-on oral drug with no weight gain or other troublesome side effects, allowing it to rapidly capture a large market share by addressing a key unmet need of patients. • Sanofi: Similar to Merck, Sanofi has achieved the number two spot in the entire diabetes therapeutics market with the success of their blockbuster insulin Lantus. Lantus was the first long-acting basal insulin, greatly increasing the convenience of insulin therapy.
  8. 8. 8NC67-52 Rapid Basal Parenteral Oral/transmucosal/inhaled Pre-Mix/Intermediate Total Type 2 Diabetes Therapeutics Market: Competitive Landscape—Insulin Segment, Marketed and Pipeline Products by Type, Global, 2012 Competitive Landscape—Insulin Segment Marketed and Pipeline Products (continued) Source: Frost & Sullivan Phase 1 Phase 3 MarketPreregistrationPhase 2 Tresiba (EU, JP) (NVO) Tresiba (US) (NVO) NN1954 (NVO) Levemir (NVO) Lantus (SNY) LY2605541 (BING/LLY) NN1953 (NVO) SuliXen (Xenetic Biosciences) LAI287 (NN1436) (NVO) Nodlin (NOD Pharmaceuticals) LY2963016 (BING/LLY) IDegLira (NVO) HOE901/AVE0010 (SNY/Zealand) Humalog (LLY) Novolog (NVO) Apidra (SNY) BIOD-238 (Biodel) Novolog Mix 75/25 (NVO) Humalog 50/50 (LLY) Humalog25/75 (LLY) Humulin N (LLY) BIOD-123 (Biodel) Ryzodeg (EU, JP) (NVO) Ryzodeg (US) (NVO) ORMD-0801 (Oramed) Afrezza (Mannkind) BIOD-250 (Biodel) NN1218 (NVO Oral-lyn (Generex) IN-105 (Biocon/BMY) Insuman (SNY) Humulin R (LLY) HM12460A (LAPS-Insulin) (Hanmi Pharmaceutical) Insulin glargine U-300 (SNY)
  9. 9. 9NC67-52 Pipeline Analysis—Insulin Segment Products in Late Stage Clinical Development Product Company MOA/Class Phase Dosing/ Administration Comments Afrezza Mannkind, Emisphere Technologies Rapid-acting insulin analogue Phase 3 Inhalation Potential first-in-class inhalable insulin IDegLira (insulin degludec + liraglutide) Novo Nordisk Basal insulin + GLP-1 analogue fixed combination Phase 3 SC injection once daily Complimentary combination; potential superior efficacy among all anti-diabetics Insulin glargine U- 300 Sanofi Basal insulin Phase 3 SC injection once daily Concentrated formulation with improved PK/PD LY2605541 (insulin peglispro) Eli Lilly Basal insulin analogue Phase 3 SC injection once daily Liver-targeted; potential for improved outcomes, particularly for liver-specific insulin resistance LY2963016 (insulin glargine) Boehringer Ingelheim/Eli Lilly Basal insulin analogue Phase 3 SC injection once daily Biosimilar Lantus Oral-lyn Generex Rapid-acting insulin analogue Phase 3 Transmucosal (buccal spray) Needle-less administration, but multiple sprays per dose required; possible absorption issues Source: Frost & Sullivan Total Type 2 Diabetes Therapeutics Market: Insulin Segment, Late Stage Product Synopsis, Global, 2012
  10. 10. 10NC67-52 Pipeline Analysis—Insulin Segment Products in Mid–stage Clinical Development Product Company MOA/Class Phase Dosing/ Administration Comments BIOD-123 Biodel Ultra-rapid-acting recombinant human insulin formulation Phase 2 SC injection Absorption 64% faster than Humalog; improved injection site reaction profile compared to first generation formulation (Linjeta) FIAsp/NN1218 Novo Nordisk Ultra-rapid –acting insulin aspart Phase 1 (Phase 3 ready) SC injection Achieved proof-of-concept in type 1 and type 2 diabetes; Three Phase 3 trials to be initiated Q3-2013 HOE901/AVE0010 FC (Lantus + Lyxumia ) Sanofi, Zealand Basal insulin + GLP-1 analogue fixed combination Phase 2 SC injection once daily Complimentary combination; injection device in development that allows for adjustment of insulin dose with a fixed lixisenatide dose IN-105 Biocon, Bristol-Myers Squibb Prandial insulin conjugate Phase 2 Oral (single tablet) Liver-targeted ORMD-0801 Oramed Basal insulin Phase 2 Oral (2 pills/day) Oral GLP-1 also in development; potential for insulin + GLP-1 FDC pill Source: Frost & Sullivan Total Type 2 Diabetes Therapeutics Market: Insulin Segment, Mid–stage Product Synopsis, Global, 2012
  11. 11. 11NC67-52 Pipeline Analysis—Insulin Segment Products in Early Stage Clinical Development Product Company MOA/Class Phase Dosing/ Administration Comments BIOD-238 Biodel Ultra-rapid-acting insulin analogue (Humalog-based) Phase 1 SC injection Reduced EDTA and no MgSO4 BIOD-250 Biodel Ultra-rapid-acting insulin analogue Phase 1 SC injection MgSO4 added HM12460A (LAPS-Insulin) Hanmi Pharmaceutical Ultra-long-acting insulin Phase 1 SC injection, once weekly Preclinical evidence of comparable glucose lowering versus daily basal insulins NN1436/LAI287 Novo Nordisk Basal insulin analogue Phase 1 SC injection, once weekly Phase 1 trial in type 1 diabetes patients underway NN1953/OI338GT Novo Nordisk, Merrion Pharmaceuticals Basal insulin analogue Phase 1 Oral (tablet) Multiple dose Phase 1 trial underway; developed using Merrion’s Gastrointestinal Permeation Enhancement Technology (GIPET) Source: Frost & Sullivan Total Type 2 Diabetes Therapeutics Market: Insulin Segment, Early Stage Product Synopsis, Global, 2012
  12. 12. 12NC67-52 Pipeline Analysis—Insulin Segment Products in Early Stage Clinical Development (continued) Product Company MOA/Class Phase Dosing/ Administration Comments NN1954/OI362GT Novo Nordisk, Merrion Pharmaceuticals Basal insulin analogue Phase 1 Oral (tablet) Single dose Phase 1 study completed; developed using Merrion’s GIPET technology Nodlin NOD Pharmaceuticals Basal insulin Phase 1 (China) Oral Technology encapsulates macromolecules into bio- adhesive nano-particles SuliXen Xenetic Biosciences Basal insulin analogue Phase 1 SC injection Potentially less immunogenic BIOD-530 Biodel Ultra-rapid-acting concentrated insulin Preclinical SC injection or pump; U-400 Potential to be the only concentrated insulin for pump use Source: Frost & Sullivan
  13. 13. 13NC67-52 Parenteral Oral Generics are not included. Source: Frost & Sullivan Total Type 2 Diabetes Therapeutics Market: Competitive Landscape—Non–Insulin Segment, Late Stage and Marketed Products by Drug Class, Global, 2012 Competitive Landscape—Non–Insulin Segment Late Stage and Marketed Products TZD/PPAR DPP-4 GLP-1 FDC Miglitinide Other* SGLT2 Januvia (MRK) Nesina (Takeda/ Furiea) Onglyza (BMY/AZN) Galvus (NVS) Tradjenta (BING/LLY) Zemiglo (LG Life Sciences) Tenelia (Mitsubishi Tanabe/Daiichi Sankyo) Kazano (Takeda/Furiex) Avandamet (GSK) Janumet / Janumet XR (MRK) Kombiglyze (BMY/AZN) Avandaryl/Avaglim (GSK) Oseni/Liovel (Takeda) Actoplus Met/Actoplus Met XR/Competact XR (Takeda) Juvisync (MRK) Duetact (Takeda) Jentadueto (BING/LLY) Eucreas/GalvusMet (Novartis) Forxiga (EU) (BMY/AZN) Prandin/NovoNorm (NVO) Starlix (Novartis) Glufast Kissei Pharmaceutical Cycloset (Santarus) Symlin (BMY/AZN) Avandia (GSK) Actos (Takeda) Bydureon (BMY) Victoza (NVO) Lyxumia (SNY) Byetta (BMY) Pre-registration Phase 3 Market Tandemact+alogliptin (Takeda) Forxiga + MET (BMY/AZN) Empagliflozin + linagliptin (BING/LLY) Glimepiride + atorvastatin (GSK) Canagliflozin/MET (US) (JNJ) Dulaglutide (LLY) Albiglutide (EU) (GSK)Canagliflozin/MET (EU) (JNJ) Empagliflozin + MET (BING/LLY) IDegLira (NVO) Tradjenta + PIO (BING/LLY) Gemigliptin + MET (LG Life Sciences) ITCA 650 (Intarcia Therapeutics) Trelagliptin (JP) (Takeda/Furiex) MK-3102 (MRK) Semaglutide (NVO)Empagliflozin (BING/LLY) Aleglitazar (Roche) Albiglutide (US) (GSK) TAK-875 (Takeda) Ipragliflozin (Astellas/Kotobuki Pharmaceutical) Luseogliflozin (Taisho/NVS) Invokana (EU) (JNJ) Tofogliflozin (Chugai/Kowa/SNY) Invokana (US) (JNJ) Forxiga (US) (BMY/AZN) * Classes other than those listed or undisclosed
  14. 14. 14NC67-52 Marketed Product Synopsis—Non–insulin Segment Add–on Products Product Company MOA/Class First Launch Markets US Patent Expiry Actos (pioglitazone) Takeda TZD 1999 Worldwide Expired Actoplus Met (pioglitazone/ metformin IR) Takeda FDC (TZD + MET) 2005 Worldwide Expired Actoplus Met XR/ Competact XR (pioglitazone/ metformin XR) Takeda, Watson FDC (TZD + MET) 2010 Worldwide 2026 Avandia (rosiglitazone) GlaxoSmithKline TZD 1999 Worldwide Expired Avandamet (rosiglitazone/ metformin IR) GlaxoSmithKline FDC (TZD + MET) 2002 Worldwide Expired Avandaryl/Avaglim (rosiglitazone/ glimepiride) GlaxoSmithKline, Sanofi FDC (TZD + SU) 2006 Worldwide Expired Bydureon (exenatide XR) Bristol-Myers Squibb/Eli Lilly GLP-1 2011 Worldwide 2025 Source: Frost & Sullivan Total Type 2 Diabetes Therapeutics Market: Non-insulin Segment, Add-on Marketed Product Synopsis, Global, 2012
  15. 15. 15NC67-52 Marketed Product Synopsis—Non–insulin Segment Add–on Products (continued) Product Company MOA/Class First Launch Markets US Patent Expiry Byetta (exenatide) Bristol-Myers Squibb GLP-1 2005 Worldwide 2017 Cycloset (bromocriptine mesylate) Santarus Other (dopamine receptor agonist) 2010 Worldwide 2015 Duetact (pioglitazone/ glimepiride) Takeda FDC (TZD + SU) 2006 Worldwide Expired Eucreas/GalvusMet (vildagliptin/ metformin) Novartis FDC (DPP-4 + MET) 2007 Worldwide ex-US Unknown Forxiga (dapagliflozin) Bristol-Myers Squibb, AstraZeneca SGLT2 2012 Europe (US approval pending) 2020 Galvus (vildagliptin) Novartis DPP-4 2007 Worldwide ex-US Unknown Glufast (mitiglinide) Kissei Pharmaceutical Meglitinide — APAC Unknown Invokana (canagliflozin) Johnson & Johnson SGLT2 2013 US (EU approval pending) 2024 Source: Frost & Sullivan
  16. 16. 16NC67-52 Product Company MOA/Class First Launch Markets US Patent Expiry Janumet XR (sitagliptin + metformin XR) Merck, Depomed FDC (DPP-4 + MET) 2012 Worldwide 2022 Janumet (sitagliptin/metformin) Merck FDC (DPP-4 + MET) 2007 Worldwide 2022 Januvia (sitagliptin) Merck DPP-4 2006 Worldwide 2022 Jentadueto (linagliptin/metformin) Boehringer Ingelheim/Eli Lilly FDC (DPP-4 + MET) 2012 Worldwide 2025 Juvisync (sitagliptin/ simvastatin) Merck FDC (DPP-4 + statin) 2009 (JP) 2011 (US) Worldwide 2026 Kazano (alogliptin/metformin) Takeda FDC (DPP-4 + MET) 2013 US 2016 Kombiglyze XR (saxagliptin/metformin XR) Bristol-Myers Squibb/ AstraZeneca FDC (DPP-4 + MET) 2011 Worldwide 2023 Lyxumia (lixisenatide) Sanofi GLP-1 2013 Europe (US approval pending) 2020 Nesina (alogliptin) Takeda DPP-4 2010 Japan, US 2016 Source: Frost & Sullivan Marketed Product Synopsis—Non–insulin Segment Add–on Products (continued)
  17. 17. 17NC67-52 Product Company MOA/Class First Launch Markets US Patent Expiry Onglyza (saxagliptin) Bristol-Myers Squibb/ AstraZeneca DPP-4 2009 Worldwide 2021 Oseni/Liovel (alogliptin/ pioglitazone) Takeda FDC (DPP-4 + TZD) 2011 Japan, US 2016 Prandin/NovoNorm (repaglinide) Novo Nordisk Meglitinide 1998 US, Europe Expired Starlix (neteglinide) Novartis Meglitinide 2000 Worldwide Expired Symlin (pramlintide acetate) Bristol-Myers Squibb, AstraZeneca Other (amylin receptor antagonist) 2005 Worldwide 2019 Tenelia (Teneligliptin/MP-513) Mitsubishi Tanabe DPP-4 2012 Japan Unknown Tradjenta (linagliptin) Boehringer Ingelheim/Eli Lilly DPP-4 2011 Worldwide 2025 Victoza (liraglutide) Novo Nordisk GLP-1 2009 Worldwide 2022 Zemiglo (gemigliptin) LG Life Sciences DPP-4 2012 Turkey, Korea, China Unknown Source: Frost & Sullivan Marketed Product Synopsis—Non–insulin Segment Add–on Products (continued)
  18. 18. 18NC67-52 Timeline of Product Launches 2018201720162015201420132010 2011 2012 Japan launchEU launch Total Type 2 Diabetes Therapeutics Market: Timeline of Product Launches, Global, 2010–2018 The base year is 2012. Source: Frost & Sullivan Key Takeaway: The diabetes market will see a steady stream of new product launches over the next six years. FIAsp Affrezza IDegLira Semaglutide Aleglitazar Empagliflozin Dulaglutide Albiglutide ITCA 650 Invokana MK-3102TAK-875 LyxumiaLyxumia Bydureon Janumet XRTradjenta Jentadueto Juvisync Nesina Nesina Kazano Oseni Forxiga Note: Product launches after mid-2013 are estimated based on regulatory filing dates and/or publically communicated estimates US launch First Global Launch Invokana Invokana Empagliflozin Bydureon Bydureon Nesina Forxiga Forxiga Tradjenta Tradjenta Lyxumia Albiglutide
  19. 19. 19NC67-52 2005 2010 2015 2020 20252000 2030 Patent Expirations Total Type 2 Diabetes Therapeutics Market: Patent Expirations, Insulin Segment, Global, 2000–2030 Source: Frost & SullivanYear Patent Expirations Insulin SegmentProduct Humulin 2000 Humalog 2013 Novolog/NovoRapid 2014 Lantus 2015 Afrezza 2020 Apidra 2023 Levemir 2019 Insulin/insulin analogue
  20. 20. 20NC67-52 2005 2010 2015 2020 20252000 2030 Patent Expirations Total Type 2 Diabetes Therapeutics Market: Patent Expirations, Non-insulin Segment, Global, 2000–2030 Source: Frost & Sullivan Year Patent Expirations Non–insulin Segment * Market exclusivity to 2018 Product Other classTZD GLP-1 DPP-4 SGLT2 Amaryl 2005 Glucophage XR 2003 Glucotrol XL 2003 Glucobay 2007 Nesina 2016* Cycloset 2015 Starlix 2009 Avandia 2012 Prandin 2011 Actos 2011 Glumetza 2016 Juvisync 2026 Forxiga 2020 Galvus 2020 Symlin 2019 Fortamet 2018 Byetta 2017 Victoza 2022 Januvia 2022 Onglyza 2021 Lyxumia 2020 Jentadueto 2025 Tradjenta 2025 Bydureon 2025 Invokana 2024 Kombiglyze XR 2023 Actoplus Met XR 2026
  21. 21. 21NC67-52 CardiovascularOutcomesTrial 2015 20202005 Patent Expirations Total Type 2 Diabetes Therapeutics Market: Cardiovascular Outcomes Trials Timeline, Global, 2012 Source: Clinicaltrials.gov and Frost & Sullivan analysisYear Cardiovascular Outcomes Trials Timeline 2010 TECOS (N = 14,000)Sitagliptin EXAMINE (N = 5,400)Alogliptin CANVAS (N = 4,330)Canaglifozin EXSCEL (N = 9,500)Exenatide ELIXA (N = 6,000)Lixisenatide N = 7,000Empagliflozin REWIND (N = 9,622)Dulaglutide (N = 5,000)TAK-875 MK-3102-018 AM5 (N = 4,000)MK-3102 AleCardio (N = 19,000)Aleglitazar SUSTAIN (N = 3,260)Semaglutide (N = 2,000)ITCA 650 DECLARE (N = 17,150)Dapagliflozin CAROLINA N = 6,000Linagliptin LEADER N = 9,340Liraglutide SAVOR (N = 16,500)Saxagliptin ORIGIN (N = 12,537) Insulin glargine
  22. 22. 22NC67-52 Comparative Product Profiles of Promising Late-stage Candidates Source: Frost & Sullivan Drug (Company) Advantages Disadvantages IDegLira (Novo Nordisk) • Superior efficacy versus all known antidiabetics • Physician acceptance of the insulin/GLP- 1 combination • Regulatory delay ITCA 650 (Intarcia Therapeutics) • Convenience of once yearly implantation • Physician familiarity with mechanism • Inconvenience of removal if immediately necessary Forxiga (Bristol-Myers Squibb/AstraZeneca) and Invokana (Johnson & Johnson) • Weight loss and BP lowering • Convenience of once-daily oral therapy • Ease of combination therapy • Unknown long term safety profile • Potential for dapagliflozin cancer signal to be class effect • Genitourinary side effects • Contraindicated in certain patient types (renal insufficiency) LY2605541 (Eli Lilly) • Liver-targeted action • Improved efficacy in liver-insulin resistance • Weight loss • Unknown long term safety/efficacy profile Total Type 2 Diabetes Therapeutics Market: Comparative Product Profiles of Promising Late-stage Candidates, Global, 2012
  23. 23. 23NC67-52 Included below please find the detailed Table of Contents for Analysis of the Type 2 Diabetes Therapeutics Market: Global Market Opportunities for Differentiated Therapeutics If interested in more information, contact: Jennifer C...“ Additional sources of information on diabetes: • European Diabetes Diagnostics Market • Indian Diabetes Market • European Diabetes Therapeutics Market • 2010 U.S. Type 2 Diabetes Patients' Choice: Awareness, Usage, and Preferences of Injection Pens •Additional Frost & Sullivan offerings: • Talk to an analyst • Take our DNA Survey • Arrange a Growth Workshop • Explore the Growth Excellence Matrix 2.0 • Attend a relevant live or virtual event • Explore Healthcare Growth Consulting opportunities Learn More—Next Steps Source: Frost & Sullivan
  24. 24. 24NC67-52 Research Team Debbie Toscano Senior Industry Analyst Life Sciences Lead Analyst Europe Analyst Gulifeiya Abuduxike Industry Analyst Life Sciences Aiswariya Chidambaram Senior Research Analyst Life Sciences Blair Dong Consulting Analyst Life Sciences APAC Analyst China Analyst Research Director Jennifer Lazar Brice Global Program Director Life Sciences Manisha Rawat Research Analyst Life Sciences India Analyst Strategic Review Committee Leader Greg Caressi Senior Vice President Healthcare & Life Sciences Ankita Kothari Research Associate Life Sciences India Analyst
  25. 25. 25NC67-52 Contents Section Slide Number Executive Summary 39 • Key Findings 40 • Scope and Segmentation 42 • Key Questions This Study Will Answer 43 • Market Engineering Measurements 44 • CEO’s Perspective 46 • Key Companies to Watch 47 • Executive Summary—3 Big Predictions 48 Market Overview 49 • Market Background 50 • Market Segmentation 52 • Market Segmentation Discussion 53 • Global Market Perspective 56 • Defining Healthcare Trends in the Future 57
  26. 26. 26NC67-52 Contents (continued) Section Slide Number Competitive Playbook 58 • New Market Opportunities 59 • Merger, Acquisition, and Partnership Assessment 61 Driver, Restraints, and Trends—Total Market 62 • Market Drivers 63 • Market Restraints 64 Forecasts and Trends—Total Market 65 • Market Engineering Measurements 66 • Forecast Assumptions and Definitions 68 • Revenue Forecast 69 • Revenue Forecast Discussion 70 • Percent Revenue Forecast by Region 72 • Revenue Forecast by Region 73
  27. 27. 27NC67-52 Contents (continued) Section Slide Number Competitive Environment 74 • Competitive Landscape—Insulin Segment: Marketed and Pipeline Products 75 • Marketed Product Synopsis—Insulin Segment 77 • Marketed Product Profiles—Insulin Segment: Rapid-acting Insulin 79 • Marketed Product Profiles—Insulin Segment: Intermediate-acting/Premix Insulin 80 • Marketed Product Profiles—Insulin Segment: Basal Insulin 81 • Pipeline Analysis—Insulin Segment: Products in Late Stage Clinical Development 82 • Pipeline Analysis—Insulin Segment: Products in Mid-stage Clinical Development 83 • Pipeline Analysis—Insulin Segment: Products in Early Stage Clinical Development 84 • Competitive Landscape—Non–insulin Segment: Count of Marketed and Pipeline Products 86 • Competitive Landscape—Non–Insulin Segment: Late Stage and Marketed Products 87 • Competitive Landscape—Non–Insulin Segment: Early Stage Pipeline Products 88 • Marketed Product Synopsis—Non–insulin Segment: First Line Standard of Care Products 89 • Marketed Product Synopsis—Non–insulin Segment: Add–on Products 90
  28. 28. 28NC67-52 Contents (continued) Section Slide Number • Marketed Product Profiles—Non-insulin Segment: DPP-4 Class 94 • Marketed Product Profiles—Non-insulin Segment: GLP-1 Class 96 • Marketed Product Profiles—Non-insulin Segment: SGLT2 Class 98 • Pipeline Analysis—Non–Insulin Segment: Products in Late Stage Clinical Development 99 • Pipeline Analysis—Non–Insulin Segment: Products in Mid-stage Clinical Development 101 • Pipeline Analysis—Non–Insulin Segment: Products in Early Stage Clinical Development 105 • Market Share Evolution 110 • Market Share Analysis 111 • Top Competitors 112 • Timeline of Product Launches 113 • Patent Expirations: Insulin Segment 114 • Patent Expirations: Non–insulin Segment 115 • Exclusivity Periods of Key Products: Insulin Segment 116
  29. 29. 29NC67-52 Contents (continued) Section Slide Number • Exclusivity Periods of Key Products: Non–insulin Segment 117 • Cardiovascular Outcomes Trials Timeline 119 • Comparative Product Profiles of Promising Late-stage Candidates 120 • Comparative Efficacy Analysis 121 • Comparative Efficacy Analysis Discussion 123 Insulin Segment Breakdown 124 • Insulin Segment Key Findings 125 • Market Engineering Measurements 126 • Revenue Forecast 127 • Revenue Forecast Discussion 128 Non–insulin Segment Breakdown 129 • Non-insulin Segment Key Findings 130 • Market Engineering Measurements 131 • Revenue Forecast 132 • Revenue Forecast Discussion 133
  30. 30. 30NC67-52 Contents (continued) Section Slide Number United States Breakdown 134 • Insulin Segment Revenue Forecast 135 • Insulin Segment Revenue Forecast by Class 136 • Insulin Segment Revenue Forecast Discussion 137 • Insulin Segment Type 2 Diabetes Prevalence and Treated Patient Forecast 138 • Insulin Segment Type 2 Diabetes Prevalence and Treated Patient Forecast Discussion 139 • Non-insulin Segment Revenue Forecast 140 • Non-insulin Segment Revenue Forecast by Class 141 • Non-insulin Segment Revenue Forecast Discussion 142 • Non-insulin Segment Type 2 Diabetes Prevalence and Treated Patient Forecast 143 • Non-insulin Segment Type 2 Diabetes Prevalence and Treated Patient Forecast Discussion 144 • Pricing Analysis 145 • Market Analysis 146 • PESTLE Analysis 147
  31. 31. 31NC67-52 Contents (continued) Section Slide Number United Kingdom Breakdown 148 • The United Kingdom Diabetes Outlook 149 • Insulin Segment Revenue Forecast 150 • Insulin Segment Revenue Forecast Discussion 151 • Non-insulin Segment Revenue Forecast 152 • Non-insulin Segment Revenue Forecast Discussion 153 • Regulatory Policy Framework 154 • Pricing and Reimbursement 155 • Type 2 Diabetes Prevalence Forecast 156 • Type 2 Diabetes Prevalence Forecast Discussion 157 • Market Analysis 159
  32. 32. 32NC67-52 Contents (continued) Section Slide Number Germany Breakdown 160 • Germany Diabetes Outlook 161 • Insulin Segment Revenue Forecast 162 • Insulin Segment Revenue Forecast Discussion 163 • Non-insulin Segment Revenue Forecast 164 • Non-insulin Segment Revenue Forecast Discussion 165 • Regulatory Policy Framework 166 • Pricing and Reimbursement 167 • Type 2 Diabetes Prevalence Forecast 168 • Type 2 Diabetes Prevalence Forecast Discussion 169 • Market Analysis 171
  33. 33. 33NC67-52 Contents (continued) Section Slide Number France Breakdown 172 • France Diabetes Outlook 173 • Insulin Segment Revenue Forecast 174 • Insulin Segment Revenue Forecast Discussion 175 • Non-insulin Segment Revenue Forecast 176 • Non-insulin Segment Revenue Forecast Discussion 177 • Regulatory Policy Framework 178 • Pricing and Reimbursement 179 • Type 2 Diabetes Prevalence Forecast 180 • Type 2 Diabetes Prevalence Forecast Discussion 181 • Market Analysis 183
  34. 34. 34NC67-52 Contents (continued) Section Slide Number Italy Breakdown 184 • Italy Diabetes Outlook 185 • Insulin Segment Revenue Forecast 186 • Insulin Segment Revenue Forecast Discussion 187 • Non-insulin Segment Revenue Forecast 188 • Non-insulin Segment Revenue Forecast Discussion 189 • Regulatory Policy Framework 190 • Pricing and Reimbursement 191 • Type 2 Diabetes Prevalence Forecast 192 • Type 2 Diabetes Prevalence Forecast Discussion 193 • Market Analysis 195
  35. 35. 35NC67-52 Contents (continued) Section Slide Number Spain Breakdown 196 • Spain Diabetes Outlook 197 • Insulin Segment Revenue Forecast 198 • Insulin Segment Revenue Forecast Discussion 199 • Non-insulin Segment Revenue Forecast 200 • Non-insulin Segment Revenue Forecast Discussion 201 • Regulatory Policy Framework 202 • Pricing and Reimbursement 203 • Type 2 Diabetes Prevalence Forecast 204 • Type 2 Diabetes Prevalence Forecast Discussion 205 • Market Analysis 207
  36. 36. 36NC67-52 Contents (continued) Section Slide Number Benelux Breakdown 208 • Benelux Diabetes Outlook 209 • Insulin Segment Revenue Forecast 210 • Insulin Segment Revenue Forecast Discussion 211 • Non-insulin Segment Revenue Forecast 212 • Non-insulin Segment Revenue Forecast Discussion 213 • Regulatory Policy Framework 214 • Pricing and Reimbursement 217 • Type 2 Diabetes Prevalence Forecast 220 • Type 2 Diabetes Prevalence Forecast Discussion 221 • Market Analysis 223
  37. 37. 37NC67-52 Contents (continued) Section Slide Number Scandinavia Breakdown 224 • Scandinavia Diabetes Outlook 225 • Insulin Segment Revenue Forecast 226 • Insulin Segment Revenue Forecast Discussion 227 • Non-insulin Segment Revenue Forecast 228 • Non-insulin Segment Revenue Forecast Discussion 229 • Regulatory Policy Framework 230 • Pricing and Reimbursement 234 • Type 2 Diabetes Prevalence Forecast 238 • Type 2 Diabetes Prevalence Forecast Discussion 239 • Market Analysis 241
  38. 38. 38NC67-52 Contents (continued) Section Slide Number China Breakdown 242 • Market Overview 243 • Insulin Segment Revenue Forecast 244 • Insulin Segment Revenue Forecast Discussion 245 • Non-insulin Segment Revenue Forecast 246 • Non-insulin Segment Revenue Forecast Discussion 247 • Pricing Analysis 248 • Type 2 Diabetes Prevalence and Treated Patient Forecast 249 • Type 2 Diabetes Prevalence and Treated Patient Forecast Discussion 250 • Market Analysis 251
  39. 39. 39NC67-52 Contents (continued) Section Slide Number South Korea Breakdown 252 • South Korea Diabetes Outlook 253 • Insulin Segment Revenue Forecast 254 • Insulin Segment Revenue Forecast Discussion 255 • Non-insulin Segment Revenue Forecast 256 • Non-insulin Segment Revenue Forecast Discussion 257 • Pricing Analysis 258 • Type 2 Diabetes Prevalence and Treated Patient Forecast 259 • Type 2 Diabetes Prevalence and Treated Patient Forecast Discussion 260 • Market Analysis 262
  40. 40. 40NC67-52 Contents (continued) Section Slide Number Malaysia Breakdown 264 • Malaysia Diabetes Outlook 265 • Insulin Segment Revenue Forecast 266 • Insulin Segment Revenue Forecast Discussion 267 • Non-insulin Segment Revenue Forecast 268 • Non-insulin Segment Revenue Forecast Discussion 269 • Pricing Analysis 270 • Type 2 Diabetes Prevalence and Treated Patient Forecast 271 • Type 2 Diabetes Prevalence and Treated Patient Forecast Discussion 272 • Market Analysis 274
  41. 41. 41NC67-52 Contents (continued) Section Slide Number Indonesia Breakdown 276 • Indonesia Diabetes Outlook 277 • Insulin Segment Revenue Forecast 278 • Insulin Segment Revenue Forecast Discussion 279 • Non-insulin Segment Revenue Forecast 280 • Non-insulin Segment Revenue Forecast Discussion 281 • Pricing Analysis 282 • Type 2 Diabetes Prevalence and Treated Patient Forecast 283 • Type 2 Diabetes Prevalence and Treated Patient Forecast Discussion 284 • Market Analysis 286
  42. 42. 42NC67-52 Contents (continued) Section Slide Number Vietnam Breakdown 287 • Vietnam Diabetes Outlook 288 • Insulin Segment Revenue Forecast 289 • Insulin Segment Revenue Forecast Discussion 290 • Non-insulin Segment Revenue Forecast 291 • Non-insulin Segment Revenue Forecast Discussion 292 • Pricing Analysis 294 • Type 2 Diabetes Prevalence and Treated Patient Forecast 295 • Type 2 Diabetes Prevalence and Treated Patient Forecast Discussion 296 • Market Analysis 298
  43. 43. 43NC67-52 Contents (continued) Section Slide Number India Breakdown 299 • Insulin Segment Revenue Forecast 300 • Insulin Segment Revenue Forecast Discussion 301 • Non-insulin Segment Revenue Forecast 302 • Non-insulin Segment Revenue Forecast Discussion 303 • Pricing Analysis 304 • Type 2 Diabetes Prevalence and Treated Patient Forecast 305 • Type 2 Diabetes Prevalence and Treated Patient Forecast Discussion 306 • Market Analysis 307 Customer and End-user Analysis 308 • KOL Commentary 309 Key Companies to Watch 310 • Companies to Watch 311
  44. 44. 44NC67-52 Contents (continued) Section Slide Number The Last Word 316 • The Last Word—3 Big Predictions 317 • The Last Word—Discussion 318 • Legal Disclaimer 321 Appendix 322 • Drivers Explained 323 • Restraints Explained 327 • Decision Support Database 331 • Additional Sources of Information on Diabetes 337 • Market Engineering Methodology 338 • Learn More—Next Steps 339
  45. 45. 45NC67-52 List of Exhibits Exhibit Slide Number Total Type 2 Diabetes Therapeutics Market: Market Engineering Measurements, Global, 2012 44 Total Type 2 Diabetes Therapeutics Market: Market Segmentation, Global, 2012 52 Total Type 2 Diabetes Therapeutics Market: Growth Rate Breakdown by Geographic Region, Global, 2012 56 Total Type 2 Diabetes Therapeutics Market: Market Outlook, Global, 2012 and 2022 57 Total Type 2 Diabetes Therapeutics Market: Game-changing Strategies, Global, 2012 60 Total Type 2Diabetes Therapeutics Market: Market Outlook, Global, 2007–2013 61 Total Type 2Diabetes Therapeutics Market: Key Market Drivers, Global, 2013—2017 63 Total Type 2Diabetes Therapeutics Market: Key Market Restraints, Global, 2013—2017 64 Total Type 2 Diabetes Therapeutics Market: Market Engineering Measurements, Global, 2012 66 Total Type 2 Diabetes Therapeutics Market: Revenue Forecast, Global, 2009–2017 69 Total Type 2 Diabetes Therapeutics Market: Major New Product Launches, Global, 2013– 2017 71
  46. 46. 46NC67-52 List of Exhibits (continued) Exhibit Slide Number Total Type 2 Diabetes Therapeutics Market: Percent Revenue Forecast by Region, Global, 2009–2017 72 Total Type 2 Diabetes Therapeutics Market: Revenue Forecast by Region, Global, 2009– 2017 73 Total Diabetes Therapeutics Market: Competitive Landscape—Insulin Segment, Count of Marketed and Pipeline Products by Type and Phase, Global, 2012 75 Total Diabetes Therapeutics Market: Competitive Landscape—Insulin Segment, Marketed and Pipeline Products by Type, Global, 2012 76 Total Type 2 Diabetes Therapeutics Market: Insulin Segment, Marketed Product Synopsis, Global, 2012 77 Total Type 2 Diabetes Therapeutics Market: Insulin Segment Marketed Product Profiles, Rapid-acting Insulin, Global, 2012 79 Total Type 2 Diabetes Therapeutics Market: Insulin Segment Marketed Product Profiles, Intermediate-acting/Premix Insulin, Global, 2012 80 Total Type 2 Diabetes Therapeutics Market: Insulin Segment Marketed Product Profiles, Basal Insulin, Global, 2012 81 Total Type 2 Diabetes Therapeutics Market: Insulin Segment, Late Stage Product Synopsis, Global, 2012 82
  47. 47. 47NC67-52 List of Exhibits (continued) Exhibit Slide Number Total Type 2 Diabetes Therapeutics Market: Insulin Segment, Mid–Stage Product Synopsis, Global, 2012 83 Total Type 2 Diabetes Therapeutics Market: Insulin Segment, Early Stage Product Synopsis, Global, 2012 84 Total Diabetes Therapeutics Market: Competitive Landscape—Non–insulin Segment, Count of Marketed and Pipeline Products by Type and Phase, Global, 2012 86 Total Diabetes Therapeutics Market: Competitive Landscape—Non–Insulin Segment, Late Stage and Marketed Products by Drug Class, Global, 2012 87 Total Diabetes Therapeutics Market: Competitive Landscape—Non–Insulin Segment, Number of Early Stage Pipeline Products by Drug Class, Global, 2012 88 Total Type 2 Diabetes Therapeutics Market: Non-insulin Segment, Standard of Care Marketed Product Synopsis, Global, 2012 89 Total Type 2 Diabetes Therapeutics Market: Non-insulin Segment, Add-on Marketed Product Synopsis, Global, 2012 90 Total Type 2 Diabetes Therapeutics Market: Non-insulin Segment Marketed Product Profiles, DPP-4s, Global, 2012 94 Total Type 2 Diabetes Therapeutics Market: Non-insulin Segment Marketed Product Profiles, GLP-1s, Global, 2012 96
  48. 48. 48NC67-52 List of Exhibits (continued) Exhibit Slide Number Total Type 2 Diabetes Therapeutics Market: Non-insulin Segment Marketed Product Profiles, SGLT2s, Global, 2012 98 Total Type 2 Diabetes Therapeutics Market: Insulin Segment, Late Stage Product Synopsis, Global, 2012 99 Total Type 2 Diabetes Therapeutics Market: Insulin Segment, Mid–Stage Product Synopsis, Global, 2012 101 Total Type 2 Diabetes Therapeutics Market: Insulin Segment, Early–Stage Product Synopsis, Global, 2012 105 Total Type 2 Diabetes Therapeutics Market: Absolute Market Share Trend by Revenue, Global, 2009 and 2012 110 Total Type 2 Diabetes Therapeutics Market: Company Market Share Analysis of Top 5 Participants, Global, 2012 111 Total Type 2 Diabetes Therapeutics Market: SWOT Analysis, Global, 2012 112 Total Type 2 Diabetes Therapeutics Market: Timeline of Product Launches, Global, 2010– 2018 113 Total Type 2 Diabetes Therapeutics Market: Patent Expirations, Insulin Segment, Global, 2000–2030 114
  49. 49. 49NC67-52 List of Exhibits (continued) Exhibit Slide Number Total Type 2 Diabetes Therapeutics Market: Patent Expirations, Non-insulin Segment, Global, 2000–2030 115 Total Type 2 Diabetes Therapeutics Market: Exclusivity Periods of Major Products, Modern Insulins, Global, 2000–2030 116 Total Type 2 Diabetes Therapeutics Market: Exclusivity Periods of Major Products, Non– insulin Classes, Global, 2000–2030 117 Total Type 2 Diabetes Therapeutics Market: Cardiovascular Outcomes Trials Timeline, Global, 2012 119 Total Type 2 Diabetes Therapeutics Market: Comparative Product Profiles of Promising Late-stage Candidates, Global, 2012 120 Total Type 2 Diabetes Therapeutics Market: Comparative HbA1c Lowering of Selected Marketed Drugs, Global, 2012 121 Insulin Segment: Percent Sales Breakdown, Global, 2012 125 Insulin Segment: Market Engineering Measurements, Global, 2012 126 Insulin Segment: Revenue Forecast, Global, 2009–2017 127 Non–insulin Segment: Percent Sales Breakdown, Global, 2012 130
  50. 50. 50NC67-52 List of Exhibits (continued) Exhibit Slide Number Non–insulin Segment: Market Engineering Measurements, Global, 2012 131 Non–insulin Segment: Revenue Forecast, Global, 2009–2017 132 Insulin Segment: Revenue Forecast, US, 2009–2017 135 Insulin Segment: Revenue Forecast by Class, US, 2009–2017 136 Insulin Segment: Prevalence and Treated Patient Forecast, US, 2009–2017 138 Non-insulin Segment: Revenue Forecast, US, 2009–2017 140 Non-insulin Segment: Revenue Forecast by Class, US, 2009–2017 141 Non–insulin Segment: Evolution of Market Share by Drug Class, US, 2012 and 2017 142 Non–insulin Segment: Prevalence and Treated Patient Forecast, US, 2009–2017 143 Total Type 2 Diabetes Therapeutics Market: Pricing Analysis, US, 2012 145 Diabetes Therapeutics Market: PESTLE Analysis, US, 2012 147 Diabetes Therapeutics Market: Diabetes Outlook, The United Kingdom, 2012 and 2030 149 Insulin Segment: Revenue Forecast, the United Kingdom, 2009–2017 150
  51. 51. 51NC67-52 List of Exhibits (continued) Exhibit Slide Number Non-insulin Segment: Revenue Forecast, the United Kingdom, 2009–2017 152 Type 2 Diabetes Therapeutics Market: Regulatory Policy Framework, the United Kingdom, 2012 154 Type 2 Diabetes Therapeutics Market: Prevalence Forecast, the United Kingdom, 2009– 2017 156 Type 2 Diabetes Therapeutics Market: Diabetes Prevalence and Patient Forecast by Age Groups, The United Kingdom, 2012 and 2017 158 Type 2 Diabetes Therapeutics Market: Diabetes Prevalence and Patient Forecast by Gender, The United Kingdom, 2012 and 2017 158 Type 2 Diabetes Therapeutics Market: Diabetes Outlook, Germany, 2012 and 2030 161 Insulin Segment: Revenue Forecast, Germany, 2009–2017 162 Non-insulin Segment: Revenue Forecast, Germany, 2009–2017 164 Type 2 Diabetes Therapeutics Market: Regulatory Policy Framework, Germany, 2012 166 Type 2 Diabetes Therapeutics Market: Prevalence Forecast, Germany, 2009–2017 168 Type 2 Diabetes Therapeutics Market: Diabetes Prevalence and Patient Forecast by Age Groups, Germany, 2012 and 2017 170
  52. 52. 52NC67-52 List of Exhibits (continued) Exhibit Slide Number Type 2 Diabetes Therapeutics Market: Diabetes Prevalence and Patient Forecast by Gender, Germany, 2012 and 2017 170 Type 2 Diabetes Therapeutics Market: Diabetes Outlook , France, 2012 and 2030 173 Insulin Segment: Revenue Forecast, France, 2009–2017 174 Non-insulin Segment: Revenue Forecast, France, 2009–2017 176 Type 2 Diabetes Therapeutics Market: Regulatory Policy Framework, France, 2012 178 Type 2 Diabetes Therapeutics Market: Prevalence Forecast, France, 2009–2017 180 Type 2 Diabetes Therapeutics Market: Diabetes Prevalence and Patient Forecast by Age Groups, France, 2012 and 2017 182 Type 2 Diabetes Therapeutics Market: Diabetes Prevalence and Patient Forecast by Gender, France, 2012 and 2017 182 Type 2 Diabetes Therapeutics Market: Diabetes Outlook, Italy, 2012 and 2030 185 Insulin Segment: Revenue Forecast, Italy, 2009–2017 186 Non-insulin Segment: Revenue Forecast, Italy, 2009–2017 188
  53. 53. 53NC67-52 List of Exhibits (continued) Exhibit Slide Number Type 2 Diabetes Therapeutics Market: Regulatory Policy Framework, Italy, 2012 190 Type 2 Diabetes Therapeutics Market: Prevalence Forecast, Italy, 2009–2017 192 Type 2 Diabetes Therapeutics Market: Diabetes Prevalence and Patient Forecast by Age Groups, Italy, 2012 and 201 194 Type 2 Diabetes Therapeutics Market: Diabetes Prevalence and Patient Forecast by Gender, Italy, 2012 and 2017 194 Type 2 Diabetes Therapeutics Market: Diabetes Outlook, Spain, 2012 and 2030 197 Insulin Segment: Revenue Forecast, Spain, 2009–2017 198 Non-insulin Segment: Revenue Forecast, Spain, 2009–201 200 Type 2 Diabetes Therapeutics Market: Regulatory Policy Framework, Spain, 2012 202 Type 2 Diabetes Therapeutics Market: Prevalence Forecast, Spain, 2009–2017 204 Type 2 Diabetes Therapeutics Market: Diabetes Prevalence and Patient Forecast by Age Group, Spain, 2012 and 2017 206 Type 2 Diabetes Therapeutics Market: Diabetes Prevalence and Patient Forecast by Gender, Spain, 2012 and 2017 206
  54. 54. 54NC67-52 List of Exhibits (continued) Exhibit Slide Number Type 2 Diabetes Therapeutics Market: Diabetes Outlook, Benelux, 2012 and 2030 209 Insulin Segment: Revenue Forecast, Benelux, 2009–2017 210 Non-insulin Segment: Revenue Forecast, Benelux, 2009–2017 212 Type 2 Diabetes Therapeutics Market: Regulatory Policy Framework, Belgium, 2012 214 Type 2 Diabetes Therapeutics Market: Regulatory Policy Framework, the Netherlands, 2012 215 Type 2 Diabetes Therapeutics Market: Regulatory Policy Framework, Luxembourg, 2012 216 Type 2 Diabetes Therapeutics Market: Prevalence Forecast, Benelux, 2009–2017 220 Type 2 Diabetes Therapeutics Market: Diabetes Prevalence and Patient Forecast by Age Groups, Benelux, 2012 and 2017 222 Type 2 Diabetes Therapeutics Market: Diabetes Prevalence and Patient Forecast by Gender, Benelux, 2012 and 2017 222 Type 2 Diabetes Therapeutics Market: Diabetes Outlook, Scandinavia, 2012 and 2030 225 Insulin Segment: Revenue Forecast, Scandinavia, 2009–2017 226 Non-insulin Segment: Revenue Forecast, Scandinavia, 2009–2017 228
  55. 55. 55NC67-52 List of Exhibits (continued) Exhibit Slide Number Type 2 Diabetes Therapeutics Market: Regulatory Policy Framework, Norway, 2012 230 Type 2 Diabetes Therapeutics Market: Regulatory Policy Framework, Sweden, 2012 231 Type 2 Diabetes Therapeutics Market: Regulatory Policy Framework, Denmark, 2012 232 Type 2 Diabetes Therapeutics Market: Regulatory Policy Framework, Finland, 2012 233 Type 2 Diabetes Therapeutics Market: Prevalence Forecast, Scandinavia, 2009–2017 238 Type 2 Diabetes Therapeutics Market: Diabetes Prevalence and Patient Forecast by Age Groups, Scandinavia, 2012 and 2017 240 Type 2 Diabetes Therapeutics Market: Diabetes Prevalence and Patient Forecast by Gender, Scandinavia, 2012 and 2017 240 Insulin Segment: Revenue Forecast, China, 2009–2017 244 Non-insulin Segment: Revenue Forecast, China, 2009–2017 246 Type 2 Diabetes Therapeutics Market: Pricing Analysis, China, 2012 248 Type 2 Diabetes Therapeutics Market: Prevalence and Treated Patient Forecast, China, 2009–2017 249
  56. 56. 56NC67-52 List of Exhibits (continued) Exhibit Slide Number Type 2 Diabetes Therapeutics Market: Range of Reported Disease Prevalence Estimates, China, 2012 250 Type 2 Diabetes Therapeutics Market: Diabetes Outlook, South Korea, 2012 and 2030 253 Insulin Segment: Revenue Forecast, South Korea, 2009–2017 254 Non-insulin Segment: Revenue Forecast, South Korea, 2009–2017 256 Type 2 Diabetes Therapeutics Market: Pricing Analysis, South Korea, 2012 258 Type 2 Diabetes Therapeutics Market: Prevalence and Treated Patient Forecast, South Korea, 2009–2017 259 Type 2 Diabetes Therapeutics Market: Diabetes Prevalence by Age Groups, South Korea, 2012 and 2030 261 Type 2 Diabetes Therapeutics Market: Diabetes Prevalence by Gender, South Korea, 2012 and 2030 261 Type 2 Diabetes Therapeutics Market: Diabetes Outlook, Malaysia, 2012 and 2030 265 Insulin Segment: Revenue Forecast, Malaysia, 2009–2017 266 Non-insulin Segment: Revenue Forecast, Malaysia, 2009–2017 268
  57. 57. 57NC67-52 List of Exhibits (continued) Exhibit Slide Number Type 2 Diabetes Market: Pricing Analysis, Malaysia, 2012 270 Type 2 Diabetes Market: Prevalence and Treated Patient Forecast, Malaysia, 2009–2017 271 Type 2 Diabetes Therapeutics Market: Diabetes Prevalence by Age Groups, Malaysia, 2012 and 2030 273 Type 2 Diabetes Therapeutics Market: Diabetes Prevalence by Gender, Malaysia, 2012 and 2030 273 Type 2 Diabetes Therapeutics Market: Diabetes Outlook, Indonesia, 2012 and 2030 277 Insulin Segment: Revenue Forecast, Indonesia, 2009–2017 278 Non-insulin Segment: Revenue Forecast, Indonesia, 2009-2017 280 Type 2 Diabetes Market: Prevalence and Treated Patient Forecast, Indonesia, 2009–2017 283 Type 2 Diabetes Therapeutics Market: Diabetes Prevalence by Age Groups, Indonesia, 2012 and 2030 285 Type 2 Diabetes Therapeutics Market: Diabetes Prevalence by Gender, Indonesia, 2012 and 2030 285 Type 2 Diabetes Therapeutics Market: Diabetes Outlook, Vietnam, 2012 and 2030 288
  58. 58. 58NC67-52 List of Exhibits (continued) Exhibit Slide Number Insulin Segment: Revenue Forecast, Vietnam, 2009–2017 289 Non-insulin Segment: Revenue Forecast, Vietnam, 2009–2017 291 Type 2 Diabetes Therapeutics Market: Pricing Analysis, Vietnam, 2012 294 Type 2 Diabetes Market: Prevalence and Treated Patient Forecast, Vietnam, 2009–2017 295 Type 2 Diabetes Therapeutics Market: Diabetes Prevalence by Age Groups, Vietnam, 2012 and 2030 297 Type 2 Diabetes Therapeutics Market: Diabetes Prevalence by Gender, Vietnam, 2012 and 2030 297 Insulin Segment: Revenue Forecast, India, 2009–2017 300 Non-insulin Segment: Revenue Forecast, India, 2009–2017 302 Type 2 Diabetes Market: Pricing Analysis, India, 2012 304 Type 2 Diabetes Market: Prevalence and Treated Patient Forecast, India, 2009–2017 305 Decision Support Database: Prevalence of Type 2 Diabetes in Thousands, Global, 2008– 2018 331 Decision Support Database: Prevalence Percent of Type 2 Diabetes, Global, 2008–2018 334

×